CryoPort (NASDAQ:CYRX) Stock Price Crosses Above 200-Day Moving Average – What’s Next?

CryoPort, Inc. (NASDAQ:CYRX) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $7.36 and traded as high as $10.27. CryoPort shares last traded at $9.94, with a volume of 370,779 shares trading hands.

Analyst Ratings Changes

A number of brokerages have weighed in on CYRX. Leerink Partnrs upgraded CryoPort from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 6th. Leerink Partners upgraded shares of CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research note on Wednesday, August 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a report on Wednesday. Stephens started coverage on CryoPort in a report on Tuesday, July 22nd. They set an “overweight” rating and a $13.00 price target on the stock. Finally, BTIG Research boosted their price target on CryoPort from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, CryoPort has a consensus rating of “Moderate Buy” and a consensus target price of $12.56.

CryoPort Trading Down 1.2%

The company has a quick ratio of 15.47, a current ratio of 16.24 and a debt-to-equity ratio of 0.39. The company has a fifty day moving average of $9.03 and a two-hundred day moving average of $7.36. The stock has a market capitalization of $497.70 million, a price-to-earnings ratio of 7.47 and a beta of 1.61.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%.The company had revenue of $45.45 million for the quarter, compared to analyst estimates of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. On average, research analysts expect that CryoPort, Inc. will post -0.99 EPS for the current year.

Insider Buying and Selling

In related news, CFO Robert Stefanovich sold 9,300 shares of the company’s stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total transaction of $80,631.00. Following the transaction, the chief financial officer owned 207,213 shares of the company’s stock, valued at $1,796,536.71. This represents a 4.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ramkumar Mandalam sold 40,728 shares of the company’s stock in a transaction on Tuesday, July 22nd. The stock was sold at an average price of $7.24, for a total value of $294,870.72. Following the transaction, the director directly owned 92,328 shares in the company, valued at $668,454.72. This represents a 30.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 80,028 shares of company stock valued at $661,252 over the last three months. 10.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company grew its holdings in CryoPort by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock valued at $136,000 after purchasing an additional 1,557 shares during the last quarter. Sierra Summit Advisors LLC grew its holdings in CryoPort by 5.0% in the first quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company’s stock valued at $274,000 after purchasing an additional 2,150 shares during the last quarter. Avanza Fonder AB grew its holdings in CryoPort by 31.4% in the second quarter. Avanza Fonder AB now owns 10,882 shares of the company’s stock valued at $81,000 after purchasing an additional 2,601 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in CryoPort by 299.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock valued at $27,000 after purchasing an additional 2,729 shares during the last quarter. Finally, MetLife Investment Management LLC grew its holdings in CryoPort by 13.8% in the first quarter. MetLife Investment Management LLC now owns 24,641 shares of the company’s stock valued at $150,000 after purchasing an additional 2,980 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.